Phase 2 Open-Label Extension Study with Donidalorsen in Patients with Hereditary Angioedema: 1 Year Versus 2 Years

The phase 2 open-label extension (OLE) study of donidalorsen in patients with Type 1/2 hereditary angioedema (HAE) (NCT04307381) revealed a 95% mean reduction in attacks and improved quality of life (QoL) with donidalorsen at Year 1. A comparison of Years 1 and 2 results is presented.